Modzatinib's Fast Track in Lichen Planus Highlights Regulatory Support Amid a Clinical and Mechanistic Void

FDA Grants Fast Track Designation to Modzatinib for Lichen Planus

Aclaris Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for modzatinib (ATI-2138) for the treatment of moderate to severe lichen planus (LP), including oral erosive LP, cutaneous LP, and lichen planopilaris. This designation aims to facilitate development and expedite the review process for therapies addressing serious conditions with unmet medical needs. Aclaris plans to initiate a phased multi-part Phase 2b trial for modzatinib in LP during the fourth quarter of 2026, marking a significant step forward in addressing this debilitating disease.

• The Fast Track designation provides significant regulatory advantages, including more frequent interactions with the FDA regarding development plans and clinical trial design, enabling a potentially more efficient path to registration. It also allows for a rolling review of a New Drug Application (NDA), where completed sections can be submitted and reviewed on an ongoing basis, and may qualify for Priority Review.
• Lichen planus is highlighted as a serious and clinically concerning disease with debilitating symptoms that severely impact patients' quality of life. A critical aspect of this designation is the current lack of any FDA-approved therapies for LP, underscoring the significant unmet medical need that modzatinib aims to address.
• Following this regulatory milestone, Aclaris Therapeutics is set to advance modzatinib into a phased multi-part Phase 2b trial for lichen planus. This trial is expected to commence in the fourth quarter of 2026, marking a crucial step forward in the clinical development of the investigational therapy.

Addressing the Significant Unmet Need in Lichen Planus

Lichen planus (LP) continues to pose substantial management challenges across its cutaneous, mucosal, and follicular subtypes, with current literature highlighting a persistent reliance on corticosteroids despite their limitations and a notable absence of robust, disease-modifying systemic alternatives. These gaps are compounded by inconsistent follow-up practices and a fragmented evidence base across LP variants.

• Limited systemic treatment options: Available therapies remain restricted in scope, underscoring a clear unmet need for safe and efficacious systemic modalities—particularly as three-quarters of incident and half of prevalent patients receive only topical therapy without escalation to systemic treatment.

• Treatment-refractory disease: LP can be resistant to first-line topical corticosteroids and subsequent anti-inflammatory approaches; even combination regimens (e.g., tacrolimus 0.1% ointment with ruxolitinib 1.5% cream over four weeks) have failed to achieve adequate symptom control in some patients, with persistent severe pruritus reported. Severe, rapidly progressive cases require early clinicopathologic confirmation and timely escalation to systemic therapy.

• Corticosteroid dependency and associated risks: Corticosteroids remain the mainstay of first-line treatment despite a recognized side-effect burden, driving ongoing search for alternative therapeutics; this concern is particularly pronounced in pediatric populations, where corticosteroid-related complications carry added risk.

• Persistent knowledge gaps: Evidence remains sparse for specific subtypes such as lichen planopilaris, where appropriate treatment strategies are poorly defined; broader data limitations also affect the evidence base guiding teledermatology-driven management of LP.

• Multifactorial etiology limiting curative intent: Oral lichen planus, in particular, reflects a multifactorial etiology that renders most available treatments symptomatic rather than curative, requiring multidisciplinary awareness among all clinicians managing the oral cavity.

• Follow-up and access disparities: Compliance with follow-up is notably lower among patients managed via asynchronous teledermatology compared to synchronous care (57.8% vs. 92.7%, p < 0.001), with younger teledermatology patients identified as a group requiring targeted strategies to improve continuity of care.

Modzatinib's Fast Track: Expediting a Solution for Lichen Planus

The standard of care for lichen planus is initiated following diagnosis, which is established by clinical examination, often with histopathologic confirmation; direct immunofluorescence may serve as an adjunct to rule out specific autoimmune diseases. Corticosteroids are the cornerstone of treatment and are considered the first-line therapy, particularly for oral lichen planus (OLP). For cutaneous and mucosal presentations, treatment often involves topical application of agents like clobetasol 0.05% cream or triamcinolone 0.1% cream, typically applied twice daily for two weeks per month to affected areas.

For cases refractory to topical corticosteroids, or for more severe presentations, therapeutic escalation is warranted. Other topical anti-inflammatory therapies, such as tacrolimus 0.1% ointment or ruxolitinib 1.5% cream, may be employed. For OLP specifically, additional modalities including retinoids, cyclosporine, and photodynamic therapy have been studied. In fulminant cases unresponsive to topical treatments, systemic agents are considered. For example, the oral JAK inhibitor upadacitinib, at a dose of 15 mg daily, has demonstrated rapid resolution of pruritus and regression of plaques within three weeks in a severe case. Despite these options, effective therapy remains a challenge, and treatment currently relies predominantly on corticosteroids. This highlights an unmet need for safe and efficacious systemic modalities to limit symptom progression and complications from extensive disease.

Aclaris Secures Fast Track for Modzatinib in Debilitating Lichen Planus

The FDA's decision to grant Fast Track Designation to modzatinib for moderate to severe lichen planus (LP) is a pivotal moment for patients grappling with this often-debilitating inflammatory condition. LP, in its various forms including oral erosive, cutaneous, and lichen planopilaris, represents a significant unmet medical need, and this designation underscores the urgency for more effective therapeutic options. For Aclaris Therapeutics, this is a powerful regulatory endorsement, signaling the potential for modzatinib to offer a meaningful advance.

Strategically, Fast Track status is a critical accelerant, designed to streamline the development and review process. This could significantly shorten modzatinib's path to market, potentially allowing Aclaris to establish an early leadership position in the LP treatment landscape. However, this expedited pathway also comes with inherent considerations. While the designation acknowledges the drug's potential, the true clinical efficacy and safety profile will only be fully elucidated in subsequent trials. The pharmaceutical industry, particularly in chronic inflammatory conditions like psoriasis, increasingly values therapies that demonstrate robust cumulative clinical benefit and favorable cost-effectiveness over time. Modzatinib will need to deliver compelling data on these fronts to secure broad adoption and payer access.

A key risk lies in the development timeline itself; with the Phase 2b trial slated for Q4 2026, there's a considerable wait for definitive clinical outcomes. This extended period creates an opening for other investigational therapies to emerge or advance, potentially intensifying the competitive landscape for LP treatments. Aclaris will need to meticulously execute its clinical program, ensuring efficient patient recruitment and robust data generation, to capitalize on this Fast Track advantage and ultimately deliver a transformative therapy for lichen planus patients.